Inclusive Body Myopathy Improvement After Stem Cell Therapy in Mumbai India
He is a case of Inclusive Body Myopathy, since last 16 years with the history of slowness in running speed and slipping of "chappals" while walking and following foot drop. Weakness is progressive in nature and now involved muscles of all 4 limbs and trunk. Since last 3 years he is bedridden. Muscle biopsy is showing Inclusive Body Myopathy and EMG-NCV reports are showing generalized primary muscle disease. His elder sister also suffering from the same problem. Neurologically, he is hypotonic and hyporeflexic. On examination: he has grade 1+ muscle power in all 4 limbs proximally and grade 0 foot muscles and grade 3 distal muscles of upper limbs. Proximal muscle weakness is more than distal. Functionally, he is dependent in all ADL and mobility. On FIM he scores 48. After Stem Cell Treatment 1. Stamina has increased. 2. He can do suspension exercises for more range of motion and with more repetition without fatigue. 3. Now he can initiate rolling. He takes less support for rolling and turning. Earlier he used to change his position 4-5 times because of discomfort, but now he needs to change his position only once at night. 4. He can initiate supine to sit. 5. He is able to perform side lying to sitting by himself upto 70%. 6. Attempted drinking water in modified manner with right hand, which he couldn #39;t do before. Stem Cell Therapy done at Dr Alok Shrama NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur ...

By: neurogenbsi

Visit link:
Inclusive Body Myopathy Improvement After Stem Cell Therapy in Mumbai India - Video

Broadcast journalist says the results are dramatic By Cheche V. Moral Philippine Daily Inquirer

DAVILA and her firstborn David at age 10

You can point a mother to the ends of the earth and it wont weaken her resolve to find that cure for her ailing child.

Broadcast journalist Karen Davilas firstborn, David, was 3 years old when he was diagnosed with Pervasive Developmental Disorder, Not Otherwise Specified (PDD/NOS) in the Autism Spectrum, a severe form of autism. The development pediatrician said there was no cure for Davids condition.

David didnt have the classic signs of autism, but clearly he wasnt developing like other children his age, says Davila. At the age of 3, he wasnt speaking spontaneously, although he could read. He had tantrums, couldnt express his needs, whether he was hungry or sad, and didnt reach out to other children his age.

Like most kids in the autism spectrum, the boy had attention difficulties. He was spaced out most of the time, and was rigid. It was so heartbreaking to see my eldest this way, she adds.

Davila refused to accept that there was no answer to her sons condition. I researched endlessly and devoted myself to making sure my son got the best possible treatment, she says. She quickly put her son on a casein- and gluten-free diet and biomedical treatment, under the care of Defeat Autism Now (DAN)-licensed doctors.

Davila explains that kids like David lack an enzyme in the body to digest casein, a protein found in cows milk, and gluten, a protein found in wheat, oats, barley and rye. When they take [casein and gluten], it feels like opium in the body, so kids feel high, theyre so hyper, get wild and are spaced out.

David, now 11, has also undergone anti-fungal treatments, and has been taking supplements and B12 injections to help his attention issues. He has also benefited from the help of occupational and speech therapists. Now in Grade 5, David is in his grade level in Multiple Intelligence School, in a smaller class ratio, according to his mother.

Early last year, Davila was offered an opportunity to try the fresh cell therapy being offered by a clinic in Germany called Villa Medica. The stem cells are harvested from lamb fetus and injected into the patient. By then, the journalist-mom had read up on the supposed benefits of stem cell on children with special needs.

Continued here:
Karen Davila resorts to stem-cell therapy for son’s autism

Dundas West Animal Hospital Stem Cell Therapy

By: MakeMeVideo

Read the original here:
Dundas West Animal Hospital Stem Cell Therapy - Video

Thelma 9 weeks after Stem Cell Therapy
I created this video with the YouTube Video Editor (www.youtube.com

By: krazykp12

More:
Thelma 9 weeks after Stem Cell Therapy - Video

Stem Cell #39;s explained part 1 on The Susana Kennedy Show on 2oceansvibe
My ever increasing curiosity with the possibilities of Stem Cell therapy recently led me to meeting up with Dr. Duncan Carmichael from The Anti-Aging Clinic in Cape town, we chatted about what stem cell #39;s are, what some of the possibilities are and more, this is part one of a series of interviews I will be releasing over the next few weeks, demystifying the myths and revealing the incredible possibilities that are actually already available to you all right now. Enjoy!From:Susana KennedyViews:1 0ratingsTime:08:32More inScience Technology

Originally posted here:
Stem Cell's explained part 1 on The Susana Kennedy Show on 2oceansvibe - Video

Sources Of Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Sources of stem cells play a critical role in determining the outcome of stem cell therapy. Without a clear idea of the sources of stem cells, it is risky to be engaged in any form of stem cells treatment. The sources of stem cells include the type of animals, the location of the animals, and the parts of the animal. For more information on sources of stem cells, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:207 9ratingsTime:04:13More inScience Technology

Read more:
Sources Of Stem Cells | Stem Cell Malaysia - Video

Stem cell discovery may revive damaged heart

(IANS) / 29 November 2012

A new discovery that tricks aging stem cells into rejuvenating mode could enable scientists to create youthful patches for damaged or diseased hearts and heal them, according to a Canadian study.

The breakthrough may enable scientists to create such life giving patches from a patients own stem cells - regardless of the patients age - while avoiding the threat of rejection, the study claims.

Stem cell therapies involving donated bone marrow stem cells run the risk of patient rejection in a portion of the population, argues Milica Radisic, associate professor of chemical engineering and applied chemistry at the University of Toronto, the Journal of the American College of Cardiology reports.

One method of avoiding such a risk has been to use cells derived from a patients own body. But until now, clinical trials of this kind of therapy using elderly patients own cells have not been a viable option, since aged cells tend not to function as well as cells from young patients, according to a Toronto statement.

If you want to treat these people with their own cells, how do you do this? asks Radisic. Its a problem that Radisic and co-researcher Ren-Ke Li think they might have an answer for: by creating the conditions for a fountain of youth reaction within a tissue culture. Li is a professor in the division of cardiovascular surgery.

Radisic and Li first create a micro-environment that allows heart tissue to grow, with stem cells donated from elderly patients at the Toronto General Hospital, where Li works.

Li and his team then tracked the molecular changes in the tissue patch cells. We saw certain aging factors turned off, states Li, citing the levels of two molecules in particular, p16 and (regucalcin) RGN, which effectively turned back the clock in the cells, returning them to robust and states.

Its very exciting research, says Radisic, who was named one of the top innovators under 35 by MIT in 2008 and winner of the 2012 Young Engineers Canada award.

Read the rest here:
Stem cell discovery may revive damaged heart

SCMOM 2012_Sistemic
Sistemic #39;s world leading expertise is on applying microRNA profiling in context with the biology, to areas where there is currently an unmet need for sophisticated tools delivering instructive and robust knowledge of the cell system. From their SistemQC trade; platform they have derived an extensive suite of tools for the cell therapy, gene therapy and bioprocessing community. SistemQC trade;, molecularly characterises cells including stem cells as well as aids in the optimization and monitoring (QC) of the manufacture process. More specifically the initial focus of SistemQC trade; by clients has been on generation of microRNA based ID markers, purity potency assessment and manufacture monitoring optimization. http://www.sistemic.co.uk Presenter: Jim Reid, Chairman and CEO, SistemicFrom:AllianceRegenMedViews:3 1ratingsTime:11:56More inScience Technology

Link:
SCMOM 2012_Sistemic - Video

Procedure Combines Point-of-Care Stem Cell Therapy and Enriched Mesenchymal Stem Cell Injection

NAMPA, ID--(Marketwire - Nov 29, 2012) - Veterinarians from Idaho Equine Hospital, including Dr. William Maupin and Dr. Stuart Shoemaker, performed the first-ever combination regenerative medicine treatment on a six-year-old Quarter Reined Cow horse that suffered a significant injury to its distal straight sesamoidean ligament.

This injury can be challenging for veterinarians to successfully treat and return the horse to athletic competition.

The veterinary team and the scientific team at Stemlogix, LLC determined that the best treatment protocol would be to treat him with point-of-care stem cell therapy using the Stemlogix In-Clinic Regenerative Medicine System and then perform a follow up treatment a few weeks later using culture expanded mesenchymal stem cells. He received a dose of the point-of-care stem cell therapy three weeks ago and three weeks later received an injection of culture expanded mesenchymal stem cells.

Stemlogix, LLC pioneered the landmark stem cell therapy treatment regimen and this is the first time this combination stem cell therapy treatment has ever been performed on a horse. The team that treated the horse believes this revolutionary treatment protocol will give him the best chance for an improved quality of life and provides the best opportunity for restoring the injured tissue back to its normal structure instead of healing with scar tissue.

"Due to the severity of the injury and the poor circulation present in the sesamoidean ligament we elected to perform a two-step therapeutic approach," said Dr. Maupin. "We first injected adipose derived stem cell therapy produced patient-side to initiate an environment of healing.

"In addition, we injected culture expanded mesenchymal stem cells. This secondary expanded and enriched mesenchymal stem cell therapy treatment may further restore normal tissue structure or actual ligament tissue."

To provide him with this groundbreaking treatment, two small fat samples were taken from the base of his tail via a minimally invasive lipoaspirate procedure. Fat tissue is the richest source of stem cells for both human patients and animal patients. One of the tissue samples was processed on-site to provide a same-day, point-of-care stem cell treatment while the other tissue sample was sent to the Stemlogix state-of-the-art cGMP laboratory where the mesenchymal stem cells were isolated and expanded for three weeks. A portion of his stem cells were also cryopreserved for future use.

The Stemlogix In-Clinic Regenerative Medicine System rapidly produces a composition of stem cells at the point-of-care containing an abundance of mesenchymal stem cells, endothelial progenitor cells, among other cell types. This assortment of stem cells provides additional growth factors and therapeutic proteins to stimulate healing. This system offers veterinarians an optimal treatment tool that is convenient and effective in treating debilitating equine diseases and injuries.

On the other hand, the culture expanded stem cell therapy contains a high number of purified mesenchymal stem cells which makes this therapy better suited for treating specific indications such as orthopedic injuries, autoimmune diseases and other degenerative diseases. Mesenchymal stem cells are multi-potent or have the ability to form into a variety of new tissues such as bone, cartilage, ligaments, and tendons.

Read this article:
Stemlogix Reports Idaho Veterinarians Perform First in U.S. Combination Regenerative Medicine Treatment on Injured Horse

Ahead of a planned five-centre nationwide trial, the Indian Council of Medical Research (ICMR) has approved a special project at the AIIMS Trauma Centre in New Delhi where stem cell therapy will be conducted on complete paraplegics and quadriplegics to try and revive limb function.

A similar trial will be conducted at the Indian Spinal Injuries Centre (ISIC) in Vasant Kunj, south-west Delhi where 21 patients have already been registered. This project too has been approved by the ICMR.

Senior ICMR scientists from the apex committee to monitor stem cell research said the five-centre trial will be coordinated from ISIC and is in the final stages of approval.

This will be the first national ICMR trial of autologous bone marrow stem cell transplant on complete quadriplegics and paraplegics. We are finalising the number of patients. The ISIC will be the coordinating centre. The next meeting has been scheduled for December 4, a senior scientist said.

An autologous stem cell transplantation is a procedure in which stem cells are removed, stored and returned to the same person.

For its project, the AIIMS Trauma Centre has registered eight patients. They will be injected with stem cells from their own bone marrow to see if the damaged neurological function can be regenerated. Doctors have cautioned that earlier trials on incomplete quadriplegics and paraplegics have not suggested significant clinical improvement.

Dr Deepak Aggarwal, associate professor of neurosurgery at the AIIMS Trauma Centre who is coordinating the study, said: We have necessary clearances from our internal ethics committee and the national apex committee for stem cell research and therapy which has members from the ICMR and Department of Biotechnology.

... contd.

Read the original:
Two Delhi centres ready to try stem cell therapy on paraplegics

SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a randomized, controlled, Phase 2 multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation (dUCBT) for hematologic malignancy. The advancement of ProHema into later-stage development builds upon positive results from a Phase 1b single-center study, interactions with the U.S. Food and Drug Administration and refinements to the product manufacturing process. The previously completed Phase 1b study achieved its primary objective of demonstrating safety and tolerability. The study also established early clinical proof-of-concept trends of accelerated neutrophil recovery, improved 100-day survival and low rates of graft-versus-host disease were evident, and durable and preferential reconstitution with ProHema occurred in 10 of 12 evaluable patients. ProHema is produced through a proprietary, two-hour, ex vivo modulation process, which has been shown to significantly activate key biological pathways involved in hematopoietic stem cell homing, proliferation and survival in preclinical models.

"Allogeneic umbilical cord blood transplantation holds great promise as a potentially curative treatment for children and adults with hematologic malignancies and many other life-threatening, non-malignant disorders," said Christian Weyer, M.D., M.A.S., President and Chief Executive Officer of Fate Therapeutics. "ProHema is being developed with the intent to improve outcomes in patients undergoing cord blood transplantation by facilitating both accelerated engraftment and durable reconstitution using a simple, point-of-care, ex vivo modulation process. The initiation of Phase 2 marks an important milestone for the company and brings us one step closer towards achieving this objective."

The Phase 2 study is expected to enroll at least 45 adult patients undergoing dUCBT for the treatment of hematologic malignancies. Patients will be randomized, with a ratio of 2:1, to receive either ProHema plus an unmanipulated cord blood unit or two unmanipulated cord blood units. The study will evaluate time to neutrophil and platelet recovery, incidence of serious infections and graft-versus-host disease, 100-day mortality and relative dominance of ProHema over the unmanipulated cord in contributing to reconstitution. Results are expected in 2013.

"The preclinical and clinical data obtained to date suggest that ProHema may address several of the unmet medical needs in the evolving field of hematopoietic stem cell transplantation," said Steven Devine, M.D., Professor of Medicine and Program Director of the Blood and Marrow Transplant Program at the Ohio State University and a principal investigator of the Phase 2 clinical study. "While further investigation is required, an intervention that enables early and durable reconstitution of the best-HLA-matched cord blood unit has the potential to improve patient outcomes and substantially enhance the therapeutic value proposition of cord blood transplant."

About ProHema

ProHema is an innovative cord blood-derived cell therapy containing pharmacologically-modulated hematopoietic stem cells (HSCs). ProHema is produced through a proprietary, two-hour, ex vivo cell modulation process that results in rapid activation of key biological pathways involved in homing, proliferation and survival of HSCs. In preclinical testing, ProHema has demonstrated the potential to accelerate engraftment and to drive durable hematopoietic reconstitution, without the need for multi-week expansion protocols. In an initial Phase 1b study in adult patients with hematologic malignancies undergoing double umbilical cord blood transplant (dUCBT), the median time to neutrophil recovery (> 500 cells/microliter) with ProHema was 17.5 days, which compares favorably to historical norms for patients undergoing dUCBT. In that study, ProHema provided the dominant source of hematopoiesis in 10 of 12 evaluable subjects, suggesting that treatment with ProHema may accelerate engraftment and drive durable and preferential reconstitution.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators. The Company's first clinical program, ProHema, is an innovative cord blood-derived cell therapy containing ex vivo pharmacologically-modulated hematopoietic stem cells and is being developed to improve hematopoietic reconstitution in patients undergoing stem cell transplant. In addition, Fate Therapeutics has preclinical programs of novel in vivo stem cell modulators for skeletal muscle regeneration and hearing restoration. To advance its discovery and development efforts, the Company applies its award-winning, proprietary, induced pluripotent stem cell technology to generate rare cell populations and model disease. Fate Therapeutics is headquartered in San Diego, CA, with a subsidiary in Ottawa, Canada. For more information, please visit http://www.fatetherapeutics.com.

Original post:
Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies

Biologic Cell
Get the best offer here redirect.viglink.com?key=f341fd9454fc162be8b38d504acbd4e1 out=http%3A%2F%2Fwww%2Eamazon%2Ecom%2Fdp%2FB0083UMZOI Product Description Biologic Cell Re-Activate your stem cells to make wrinkles disappear! Set of 4 - 1 oz. jars.Stem Cell Therapy is the newest bio-active topical cream that actually stimulates your own skin stem cells to grow smooth, supple, firm new skin.Three powerful ingredients, Phyko-AI-PF (increases skin production by 57%), Mitostime (re-activates stem cells), and Seractin (a youth compound targeted at decreasing your deepest wrinkles) all work together to help you turn back the clock.Results start to appear within 2 weeks of regular use.From:Lilliam FogleViews:2 0ratingsTime:00:58More inNews Politics

Read the original post:
Biologic Cell - Video

Stem Cell Therapy For Alzheimer #39;s Disease | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy for Alzheimer #39;s Disease is currently in research and soon there may be a cure using stem cells treatment. Stem cell therapy through non-medical channel using a legal and licensed oral placenta product has produced amazing effects on an 81 years old, stage 7 Alzheimer #39;s sufferer. The effects were shockingly effective beyond words. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:0 0ratingsTime:21:27More inScience Technology

More here:
Stem Cell Therapy For Alzheimer's Disease | Stem Cell Malaysia - Video

ZUTPHEN, the Netherlands, November 20, 2012 /PRNewswire/ --

Ghent University and Cryo-Saves collaboration overcomes the restrictions encountered in bone tissue engineering of large size bone grafts. This traditional tissue engineering (TE) is often limited to the outside region resulting in a localized, non-uniform tissue formation. For the present study, Cryo-Save provided cryopreserved stem cells that show promising results to obtain a uniform cell distribution and a high cell density in the centre of bone grafts. This will improve bone deficit treatments for large size bone grafts.

Cryo-Save, Europes leading family stem cell bank, participated in a high-level tissue engineering study, headed by Dr. Heidi A. Declercq, PhD and her team from Ghent University (group leader, Prof. Dr. M. Cornelissen), Belgium, on new practices to build artificial bone tissue with stem cells. Close collaboration between Cryo-Save and Ghent University led the company to manufacture and provide cryopreserved stem cells derived from adipose tissue (ADSC) for the study. The article "Bone grafts engineered from human adipose-derived stem cells in dynamic 3D-environments" was recently published in Biomaterials, one of the most widely read and influential scientific journal in the field of Tissue Engineering and Biomaterials.

Thanks to the work of Dr. Declercq, modular tissue engineering offers an innovative way to create large bone grafts obtained with ADSC-seeded on microcarriers in a bottom-up approach. The strategy aims to engineer small volume, high-quality microtissues and the subsequent assembly in-vitro or in-vivo into larger tissue constructs upon implantation. In this study, ADSC-seeded microcarriers were exploited to prepare modular tissues (microtissues) as building blocks followed by self-assembling into macrotissues in-vitro. As a result, Dr. Declercq demonstrated that ADSC are as good as bone marrow in bone tissue engineering application revealing similar morphology, calcification level and osteogenic genes expression but the use of ADSC can substitute the painful collection of bone marrow stem cells.

The outcomes of the study are very promising for treatment of bone deficits. Dr. Declercq sees great hopes in bone tissue engineering and says: "Modular tissue engineering is a promising approach to create large bone grafts as it encounters most of the limits in traditional tissue engineering. Moreover, the combination of adipose-derived stem cells in this bottom-up approach is excellent because adipose-derived stem cells are a great source for tissue engineering purposes. A high amount of cells with high proliferation and differentiation capacity can be obtained from abundant adipose tissue sources".

Cryo-Save is thrilled to have played a major role by providing cryopreserved ADSC for use in this study. It is an integral part of Cryo-Saves activities to support research and to collaborate with leading universities, physicians and stem cell scientists, with the aim to improve clinical applications.

Cryo-Save, the leading international family stem cell bank, stores more than 225,000 samples from umbilical cord blood, cord tissue and adipose tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Driven by its international business strategy, Cryo-Save is now represented in 40 countries on three continents, with ultra-modern processing and storage facilities in Belgium, Germany, Dubai, India and South Africa.

Cryo-Save: http://www.cryo-save.com/group

Cryo-Save Group N.V.

More:
Bone Tissue Engineering Study Led by Ghent University Improves Treatment of Bone Deficits Using Cryo-Save Stem Cells

Stem cells achieve sustained heart function improvement in heart attack patients
From Louisville - Stem cell therapy has been shown to sustain heart function improvement in heart attack patients in a phase 1 clinical presented at the AHA #39;s Scientific Sessions. The trial, known as SCIPIO for Stem Cell Infusion in Patients with Ischemic CardiOmyopathy, randomized 33 patients diagnosed with heart failure after suffering a heart attack to either cardiac stem cells or no stem cells. Researchers found that patients who received the stem cells had great improvement in their heart function, and that this improvement was sustained 2 years following infusion. Patients who did not receive stem cells had no improvement. There were no adverse effects of the treatment. One patient #39;s heart experienced such dramatic improvement that there was no sign of heart failure at all. Said Dr. Roberto Bolli, lead author of the study, "Anyone who looks at his heart now would not imagine that this patient was (ever) in heart failure or that he had a heart attack."From:insidermedicineViews:0 0ratingsTime:00:59More inScience Technology

The rest is here:
Stem cells achieve sustained heart function improvement in heart attack patients - Video

New technique to deliver stem cell therapy may help damaged eyes regain their sight
Engineers at the University of Sheffield have developed a new technique for delivering stem cell therapy to the eye which they hope will help the natural repair of eyes damaged by accident or disease.From:ResearchatSheffieldViews:0 0ratingsTime:01:31More inScience Technology

Continue reading here:
New technique to deliver stem cell therapy may help damaged eyes regain their sight - Video

NeoStem, Inc. (NYSE:NBS ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy industry, today announced that it has been awarded a two year grant totaling $1,221,854 for "Repair of Bone Defects with Human Autologous Pluripotent Very Small Embryonic-Like Stem Cells (VSEL)", grant number 2R44DE022493-02A1, from the National Institute of Dental and Craniofacial Research (NIDCR), a division of the National Institutes of Health (NIH). This peer reviewed grant is to support a Phase 2 investigation and first approved NIH clinical study of VSELsTM in humans. The study will be headed by Denis O. Rodgerson, Ph.D., Director of Grants and Academic Liaison for NeoStem, in collaboration with co-investigators Drs. Russell Taichman and Laurie McCauley of the University of Michigan. Enrollment for this study is expected to begin in 2013.

This award will fund the evaluation of VSELTM stem cells as a potential treatment for periodontitis. The product candidate, an autologous therapy derived from a patient's own stem cells, is to be developed for use in the regeneration of bone tissue damaged by this disease. The award includes $706,682 for the first year and $515,172 for the second year of the project, and will cover the cost of the Investigational New Drug (IND) submission to the FDA for the product candidate.

Dr. Denis O. Rodgerson, Director of Grants and Academic Liaison for NeoStem, said, "We are pleased and honored that NIH has agreed to support further studies on bone regeneration by using VSELTM stem cells. This is an extension of our successful NIH funded collaboration with Dr. Taichman showing the production of human bone from human VSELsTM in a mouse model."

Periodontal disease is prevalent in the U.S. and affects up to 90% of the world population. The most severe cases of periodontal disease affect between 5% and 15% of the U.S. population, or between 15 and 47 million Americans. The incidence of periodontal disease is estimated to be between 1 and 3 million Americans annually, and growing at a 7% rate each year. Studies have shown that periodontal inflammation could have a role in the initiation or progression of coronary heart disease and stroke. Market research experts have estimated that severe periodontal disease represents a market between $1.25 and $1.5 billion annually.

Dr. Russell Taichman, Major Ash Collegiate Professor and Co-Director of the Scholars Program in Dental Leadership, Department of Periodontics & Oral Medicine, University of Michigan stated, "I am thrilled for the possibilities that this award opens. The chance to continue to partner with NeoStem to further develop regenerative therapies is significant. The validation that this award brings and the opportunity to establish a proof of concept, which may impact human health, is truly rewarding." Dr. Laurie McCauley, The William K. and Mary Anne Najjar Professor, Division of Periodontics Department of Periodontics and Oral Medicine, University of Michigan added, "This novel cell based therapeutic approach looks to validate scientifically sound pre-clinical studies and provide a vital translation to improved human patient care."

NeoStem has a worldwide exclusive license to VSEL technology which uses very small embryonic-like stem cells, a heterogeneous population of stem cells found in adult bone marrow that have properties similar to those of embryonic stem cells. NeoStem has shown that very small embryonic-like stem cells can be mobilized into the peripheral blood, enabling a minimally invasive means for collecting what it believes to be an important population of stem cells that may have the potential to achieve the positive benefits associated with embryonic stem cells without the ethical or moral dilemmas or the potential negative biological effects associated with embryonic stem cells.

Dr. Robin L. Smith, Chairman and CEO of NeoStem, added, "We are very excited about this important step of funding for what will be the first human clinical study for our VSELTM technology. Not only will this study expand our knowledge of how autologous cell therapy can treat periodontitis and other bone defects, but it represents a milestone for NeoStem as we move our development of VSELTM technology beyond animal models and into the clinic, paving the way for other potential VSELTM trials."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

Excerpt from:
NeoStem Receives Notification Of $1.2 million NIH Grant Award For First Clinical Study Of VSELTM Technology In Humans

MANILA, Philippines - A ranking official of the Catholic Bishops Conference of the Philippines (CBCP) considers immoral the embryonic stem cell therapy reportedly being used by politicians and actors for aesthetic purposes.

In an interview with Radio Veritas, CBCP-Episcopal Commission on Bioethics Chairman and Malolos Bishop Jose Oliveros said this medical procedure is against the belief of the Church. He said they are still assessing if the same could be said for stem cells from animals.

Pero yung sinasabi nila na pampabata sa mga politician at celebrities na sumailalim sa stem cell therapy ay immoral. Puwede namang ma-improve ang mukha ng isang tao, but it should be moral. Kapag gumamit ka ng immoral ay mali na yun, he said.

Embryo is still a maturing fetus.

He said the CBCP will come out with a pastoral statement regarding the matter once they are able to clarify certain matters with the Department of Health (DOH).

The DOH earlier warned people from using stem cells from aborted babies and human embryos.

The Philippine government will not allow the use of aborted fetuses or human embryosThere is a need to ensure that the biological raw materials are documented and validated and follow infection-free procedures, the DOH earlier said.

There is also a need to know if the materials to be injected came from animal or human tissues, it added.

Read the rest here:
Stem cell therapy is immoral - bishop

Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v
http://www.newininstitute.com.au PRP Therapy was chosen instead of a Hair Transplant to treat an area of hair loss in a female. 2 month comparison Before and After photos show a highly successful outcome. Note that continued hair growth will occur over the coming months. Another procedure will need to be performed at around the peak period: 12-18 months when growth begins to slow. Newin Institute has uniquely developed processes and protocols for PRP and Adipose Stem Cell Therapy.From:Rhett BosnichViews:0 0ratingsTime:00:55More inScience Technology

Here is the original post:
Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v - Video

Bone Marrow Stem cells for Rotator cuff Injury
George Ramsey Describes the road to recovery of his shoulder function using his own bone marrow stemcellsFrom:FLRegenerativeMedViews:0 0ratingsTime:01:55More inEducation

Read the rest here:
Bone Marrow Stem cells for Rotator cuff Injury - Video